Caitong International Asset Management Co. Ltd Invests $475,000 in Pfizer Inc. $PFE

Caitong International Asset Management Co. Ltd bought a new stake in Pfizer Inc. (NYSE:PFE) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 18,634 shares of the biopharmaceutical company’s stock, valued at approximately $475,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer in the 3rd quarter worth approximately $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer in the second quarter valued at approximately $30,000. True Wealth Design LLC lifted its position in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares in the last quarter. Darwin Wealth Management LLC purchased a new position in Pfizer during the second quarter worth approximately $32,000. Finally, Evelyn Partners Asset Management Ltd acquired a new position in Pfizer during the second quarter worth $33,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported positive topline Phase 2 results for its next‑generation CDK4 inhibitor atirmociclib in HR+/HER2‑ metastatic breast cancer — the combo reduced risk of progression or death by ~40% versus control, positioning atirmociclib as a potential successor to Ibrance and a meaningful oncology revenue driver if confirmed in later trials. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Major media and wire outlets (Reuters/BusinessWire) highlighted the trial win and its magnitude (40% risk reduction), which is driving optimism around Pfizer’s oncology strategy and helps the stock’s re‑rating story. Reuters: Pfizer experimental breast cancer drug cuts risk
• Positive Sentiment: HSBC raised its price target to $32 and maintained a Buy rating, giving institutional support and signaling ~16% upside to analysts’ consensus targets — a catalyst for near‑term buying. Benzinga: HSBC raises Pfizer PT
• Positive Sentiment: Competitive dynamics improved after a rival (Bicycle) scaled back a Padcev challenger, reducing near‑term competitive pressure on Pfizer’s fast‑selling bladder cancer drug. That lowers some downside risk to future sales. BioPharmaDive: Bicycle layoffs, Padcev challenger deprioritized
• Neutral Sentiment: Jim Cramer and other commentators noted Pfizer’s sizable pipeline (retail interest), which can boost retail flows but doesn’t change fundamentals absent confirmatory Phase 3 data or regulatory actions. Yahoo: Jim Cramer on Pfizer pipeline
• Neutral Sentiment: Coverage and attention pieces (Zacks, IP Group mentions) point to rising investor focus and deal flow benefits (e.g., prior Metsera deal), but these are incremental until monetized or reflected in guidance. Zacks: Pfizer attracting attention
• Negative Sentiment: Longer‑term risk reminder: analysts and commentators caution that Pfizer still faces revenue pressure from loss of COVID exclusivity and other patent cliffs — positive trial news helps re‑rate but does not eliminate those macro risks. The Motley Fool: Key risks for Pfizer

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PFE shares. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Barclays started coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Morgan Stanley set a $27.00 price objective on Pfizer and gave the stock a “positive” rating in a research report on Tuesday. Finally, Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.14.

Pfizer Price Performance

Shares of PFE opened at $27.47 on Wednesday. The firm has a 50-day simple moving average of $26.57 and a two-hundred day simple moving average of $25.56. The stock has a market cap of $156.21 billion, a PE ratio of 20.20 and a beta of 0.47. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period in the prior year, the business posted $0.63 EPS. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.